Navigation Links
JHP Pharmaceuticals to Produce Clinical Batches of Innovative Cardiac Drug
Date:7/25/2011

PARSIPPANY, N.J., July 25, 2011 /PRNewswire/ -- JHP Pharmaceuticals, a leading provider of contract manufacturing services for sterile injectable products has entered into an agreement with an undisclosed biotech company to produce clinical trial batches of an innovative drug used in the treatment of heart failure.

Stuart Hinchen, President and CEO of JHP stated, "We are pleased that JHP was chosen to produce clinical batches for this important customer. Our cGMP compliance record, coupled with an experienced staff, gives us an advantage in meeting customer needs throughout a product's life cycle, starting with clinical batch production."

"We know that customers want to seamlessly transition from clinical batch production to product launch and then commercialization. JHP has the right scale and experience to meet customer needs across the product life cycle."

Hinchen also noted, "During the last seven months, we successfully completed FDA and EMA audits and entered agreements with five new customers. These agreements are examples of how our approach to continuing investment allows us to focus on customer needs, which results in an internal infrastructure that supports ongoing sustainable growth."

JHP's Rochester, Michigan manufacturing site has a solid history of successful partnerships, manufacturing clinical and commercial products.

About JHP Pharmaceuticals, LLC JHP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile injectables and ophthalmic/otic products, for large and small pharmaceutical and biotech organizations.

JHP's sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse. The production facility utilizes three high-speed filling lines, a clinical filling line, four lyophilizers and an ophthalmic filling line. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development.

JHP has the capability to manufacture small-scale clinical through large-scale commercial products. JHP employs more than 330 staff in the USA in its manufacturing, product development, sales & marketing and corporate areas. For more information, please visit www.jhppharma.com. Contact: Dan Leone 973.658.3559 Bill Conway 877.906.7556 jhpcontractservices@jhppharma.com MK249
'/>"/>

SOURCE JHP Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicines Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds
2. Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada
3. Merz Pharmaceuticals Commends The Benign Essential Blepharospasm Research Foundation On 30 Years Of Community Support
4. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
5. Vanda Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011
6. ReportsnReports - The Outlook for Pharmaceuticals (BRIC, Asia, Europe, E7)
7. Amylin Pharmaceuticals to Webcast Second Quarter Results
8. Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta™ in Canada
9. Access Pharmaceuticals MuGard Included in TRICARE Prescription Drug Coverage
10. Auxilium Pharmaceuticals to Announce Second Quarter 2011 Results and Conduct Conference Call on Monday, August 1, 2011
11. Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 2017 , ... The Ellis Agency, an eastern Georgie provider of insurance management ... wide charity event with the goal of bringing in support for epilepsy patients in ... with epilepsy, recently launched a charity campaign of her own by donating her birthday ...
(Date:7/21/2017)... ... , ... Fresh Wave® IAQ today announced the launch of its innovative ... at the APPA 2017 Annual Conference and Exhibition in Booth #414. , ... the use of harsh chemicals, Fresh Wave IAQ Smoke Away Air & Fabric Liquid ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm ... the contents of its ginger ale for allegedly containing no ginger. Dr. Pepper produces ... Snapple Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how ... their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. ... on Kickstarter on Monday, July 21st. , The kit uses colorful, engaging and ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... cruciate ligament (ACL) offer patients improved quality of life five years after injury, ... Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed patients for ...
Breaking Medicine News(10 mins):